These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34018607)

  • 21. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
    Turncliff R; DiPetrillo L; Silverman B; Ehrich E
    Clin Ther; 2015 Feb; 37(2):338-48. PubMed ID: 25456560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.
    Brunette MF; Correll CU; O'Malley SS; McDonnell D; DiPetrillo L; Jiang Y; Simmons A; Silverman BL; Citrome L; Green AI
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32160422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo Characterization of the Opioid Receptor-Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations.
    Tan LA; Gajipara N; Sun L; Bacolod M; Zhou Y; Namchuk M; Cunningham JI
    Neuropsychiatr Dis Treat; 2022; 18():2497-2506. PubMed ID: 36345421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.
    Gao J; Li J; Lu X; Yang J
    Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1011-1016. PubMed ID: 36016507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine and samidorphan combination treatment: A systematic review.
    Jawad MY; Alnefeesi Y; Lui LMW; Ceban F; Chen-Li DCJ; Teopiz K; Jaberi S; Gillissie ES; Vincenzo JDD; Rosenblat JD; McIntyre RS
    J Affect Disord; 2022 Mar; 301():99-106. PubMed ID: 35007644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia.
    Li A; Ji S; Yue W; Yan H; Dong F; Ruan C; Li W; Lu W; Zhang D; Wang C
    BMJ Open; 2018 Aug; 8(8):e020070. PubMed ID: 30121590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma.
    Salem H; Samir E; Mazen DZ; Madian H; Elkhateeb AE; Elaraby M; Rasekh MI; Gamal A
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jun; 274():121105. PubMed ID: 35272122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
    Silverman BL; Martin W; Memisoglu A; DiPetrillo L; Correll CU; Kane JM
    Schizophr Res; 2018 May; 195():245-251. PubMed ID: 29158012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.
    Yagoda S; Graham C; Simmons A; Arevalo C; Jiang Y; McDonnell D
    CNS Spectr; 2021 Aug; 26(4):383-392. PubMed ID: 32393412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.
    Lobo ED; Robertson-Plouch C; Quinlan T; Hong Q; Bergstrom RF
    Paediatr Drugs; 2010 Jun; 12(3):201-11. PubMed ID: 20297865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precipitated opioid withdrawal in a patient started on olanzapine/samidorphan.
    Chambers A; Patton J; Wills BK
    Am J Emerg Med; 2024 May; 79():230.e1-230.e2. PubMed ID: 38556414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olanzapine/Samidorphan: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder.
    Pham H; Warlick H; Bermudez R; Nguyen Q; Rey JA
    J Pharm Technol; 2022 Oct; 38(5):304-313. PubMed ID: 36046346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
    Pathak S; Vince B; Kelsh D; Setnik B; Nangia N; DiPetrillo L; Puhl MD; Sun L; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):218-228. PubMed ID: 30476361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.
    An H; Fan H; Chen S; Qi S; Ma B; Shi J; Wang Z; Yang F
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):255-259. PubMed ID: 33814547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.
    Toledo FGS; Martin WF; Morrow L; Beysen C; Bajorunas D; Jiang Y; Silverman BL; McDonnell D; Namchuk MN; Newcomer JW; Graham C
    Neuropsychopharmacology; 2022 Feb; 47(3):696-703. PubMed ID: 34887529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.
    Fukumura K; Yamada T; Yokota T; Kawasaki A
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):162-174. PubMed ID: 30977959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients.
    Zang YN; Dong F; Li AN; Wang CY; Guo GX; Wang Q; Zhang YF; Zhang L; de Leon J; Ruan CJ
    Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):353-371. PubMed ID: 33677821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating Schizophrenia and Bipolar I Disorder in the Real-World Setting: Effectiveness and Safety of Olanzapine/Samidorphan Combination.
    Price MZ; Price RL
    Prim Care Companion CNS Disord; 2024 Apr; 26(2):. PubMed ID: 38579267
    [No Abstract]   [Full Text] [Related]  

  • 39. Olanzapine/samidorphan (Lybalvi) for schizophrenia and bipolar disorder.
    Med Lett Drugs Ther; 2021 Nov; 63(1638):191-192. PubMed ID: 35085217
    [No Abstract]   [Full Text] [Related]  

  • 40. An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder.
    Citrome L; Graham C; Simmons A; Jiang Y; Todtenkopf MS; Silverman B; DiPetrillo L; Cummings H; Sun L; McDonnell D
    Neuropsychiatr Dis Treat; 2021; 17():2885-2904. PubMed ID: 34526769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.